Answers are grounded in this paper and cite their sources.
Findings show nirsevimab reduces complications from respiratory infections in infants, suggesting its broader benefits.
These findings highlight the broader protective effect of nirsevimab on complications of respiratory tract infections in infants.
No takes yet. Share an insight, caveat, or question.
Lenglart et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: